世界の過敏性腸症候群(IBS)治療薬市場 2019年

QYResearchが発行した調査報告書(QYR20FB02678)
◆英語タイトル:Global Irritable Bowel Syndrome (IBS) Therapeutics Market Professional Survey Report 2019
◆商品コード:QYR20FB02678
◆発行会社(リサーチ会社):QYResearch
◆発行日:2019年11月11日(※2024年版があります。お問い合わせください。)
◆ページ数:100
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥518,000見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,250 ⇒換算¥777,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,000 ⇒換算¥1,036,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

※本調査レポートは、過敏性腸症候群(IBS)治療薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、Blautix(株)、Bekinda(IBS-D)、SYN-010、テナパノールに、用途別には、病院、研究にセグメント区分し、過敏性腸症候群(IBS)治療薬の世界市場を分析しました。


・エグゼクティブ・サマリー
・過敏性腸症候群(IBS)治療薬の世界市場概要
・過敏性腸症候群(IBS)治療薬の製造コスト構成分析
・過敏性腸症候群(IBS)治療薬の開発・製造工場分析
・主要メーカーの主な指標(生産能力、売上、価格分析)
・過敏性腸症候群(IBS)治療薬の地域別分析(生産、売上、主要メーカー、輸出・輸入)
(北米、ヨーロッパ、中国、日本国内、東南アジア、インド)
・過敏性腸症候群(IBS)治療薬のセグメント分析(種類別)
(Blautix(株)、Bekinda(IBS-D)、SYN-010、テナパノール)
・過敏性腸症候群(IBS)治療薬のセグメント分析(用途別)
(病院、研究)
・過敏性腸症候群(IBS)治療薬の主要メーカー別分析(生産拠点、製品概要、生産・売上実績)
(Abbott Laboratories、Synergy Pharmaceuticals、Sucampo Pharmaceuticals、Valeant Pharmaceuticals International、Ardelyx、Astellas Pharma、Novartis、GlaxoSmithKline、Ironwood Pharmaceuticals)
・過敏性腸症候群(IBS)治療薬の市場規模予測(2019年~2025年)
(北米、ヨーロッパ、中国、日本国内、東南アジア、インド)
・マーケティングチャネル・流通業者・顧客
・市場ダイナミクス(市場動向、機会、成長要因、課題、影響因子)
...
【レポートの概要】

IBS is a chronic disorder characterized by abdominal pain or discomfort associated with altered bowel function for at least three months, according to the Rome III criteria. Patients often experience relapse of symptoms over time.
The global Irritable Bowel Syndrome (IBS) Therapeutics market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Irritable Bowel Syndrome (IBS) Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Irritable Bowel Syndrome (IBS) Therapeutics market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Irritable Bowel Syndrome (IBS) Therapeutics in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Irritable Bowel Syndrome (IBS) Therapeutics manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Abbott Laboratories
Synergy Pharmaceuticals
Sucampo Pharmaceuticals
Valeant Pharmaceuticals International
Ardelyx
Astellas Pharma
Novartis
GlaxoSmithKline
Ironwood Pharmaceuticals

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Blautix (Strain)
Bekinda (IBS-D)
SYN-010
Tenapanor

Segment by Application
Hospital
Research

【レポートの目次】

Table of Contents

Executive Summary
1 Industry Overview of Irritable Bowel Syndrome (IBS) Therapeutics
1.1 Definition of Irritable Bowel Syndrome (IBS) Therapeutics
1.2 Irritable Bowel Syndrome (IBS) Therapeutics Segment by Type
1.2.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Production Growth Rate Comparison by Types (2014-2025)
1.2.2 Blautix (Strain)
1.2.3 Bekinda (IBS-D)
1.2.4 SYN-010
1.2.5 Tenapanor
1.3 Irritable Bowel Syndrome (IBS) Therapeutics Segment by Applications
1.3.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Consumption Comparison by Applications (2014-2025)
1.3.2 Hospital
1.3.3 Research
1.4 Global Irritable Bowel Syndrome (IBS) Therapeutics Overall Market
1.4.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Revenue (2014-2025)
1.4.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Production (2014-2025)
1.4.3 North America Irritable Bowel Syndrome (IBS) Therapeutics Status and Prospect (2014-2025)
1.4.4 Europe Irritable Bowel Syndrome (IBS) Therapeutics Status and Prospect (2014-2025)
1.4.5 China Irritable Bowel Syndrome (IBS) Therapeutics Status and Prospect (2014-2025)
1.4.6 Japan Irritable Bowel Syndrome (IBS) Therapeutics Status and Prospect (2014-2025)
1.4.7 Southeast Asia Irritable Bowel Syndrome (IBS) Therapeutics Status and Prospect (2014-2025)
1.4.8 India Irritable Bowel Syndrome (IBS) Therapeutics Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Irritable Bowel Syndrome (IBS) Therapeutics
2.3 Manufacturing Process Analysis of Irritable Bowel Syndrome (IBS) Therapeutics
2.4 Industry Chain Structure of Irritable Bowel Syndrome (IBS) Therapeutics

3 Development and Manufacturing Plants Analysis of Irritable Bowel Syndrome (IBS) Therapeutics
3.1 Capacity and Commercial Production Date
3.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Manufacturing Plants Distribution
3.3 Major Manufacturers Technology Source and Market Position of Irritable Bowel Syndrome (IBS) Therapeutics
3.4 Recent Development and Expansion Plans

4 Key Figures of Major Manufacturers
4.1 Irritable Bowel Syndrome (IBS) Therapeutics Production and Capacity Analysis
4.2 Irritable Bowel Syndrome (IBS) Therapeutics Revenue Analysis
4.3 Irritable Bowel Syndrome (IBS) Therapeutics Price Analysis
4.4 Market Concentration Degree

5 Irritable Bowel Syndrome (IBS) Therapeutics Regional Market Analysis
5.1 Irritable Bowel Syndrome (IBS) Therapeutics Production by Regions
5.1.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Production by Regions
5.1.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Regions
5.2 Irritable Bowel Syndrome (IBS) Therapeutics Consumption by Regions
5.3 North America Irritable Bowel Syndrome (IBS) Therapeutics Market Analysis
5.3.1 North America Irritable Bowel Syndrome (IBS) Therapeutics Production
5.3.2 North America Irritable Bowel Syndrome (IBS) Therapeutics Revenue
5.3.3 Key Manufacturers in North America
5.3.4 North America Irritable Bowel Syndrome (IBS) Therapeutics Import and Export
5.4 Europe Irritable Bowel Syndrome (IBS) Therapeutics Market Analysis
5.4.1 Europe Irritable Bowel Syndrome (IBS) Therapeutics Production
5.4.2 Europe Irritable Bowel Syndrome (IBS) Therapeutics Revenue
5.4.3 Key Manufacturers in Europe
5.4.4 Europe Irritable Bowel Syndrome (IBS) Therapeutics Import and Export
5.5 China Irritable Bowel Syndrome (IBS) Therapeutics Market Analysis
5.5.1 China Irritable Bowel Syndrome (IBS) Therapeutics Production
5.5.2 China Irritable Bowel Syndrome (IBS) Therapeutics Revenue
5.5.3 Key Manufacturers in China
5.5.4 China Irritable Bowel Syndrome (IBS) Therapeutics Import and Export
5.6 Japan Irritable Bowel Syndrome (IBS) Therapeutics Market Analysis
5.6.1 Japan Irritable Bowel Syndrome (IBS) Therapeutics Production
5.6.2 Japan Irritable Bowel Syndrome (IBS) Therapeutics Revenue
5.6.3 Key Manufacturers in Japan
5.6.4 Japan Irritable Bowel Syndrome (IBS) Therapeutics Import and Export
5.7 Southeast Asia Irritable Bowel Syndrome (IBS) Therapeutics Market Analysis
5.7.1 Southeast Asia Irritable Bowel Syndrome (IBS) Therapeutics Production
5.7.2 Southeast Asia Irritable Bowel Syndrome (IBS) Therapeutics Revenue
5.7.3 Key Manufacturers in Southeast Asia
5.7.4 Southeast Asia Irritable Bowel Syndrome (IBS) Therapeutics Import and Export
5.8 India Irritable Bowel Syndrome (IBS) Therapeutics Market Analysis
5.8.1 India Irritable Bowel Syndrome (IBS) Therapeutics Production
5.8.2 India Irritable Bowel Syndrome (IBS) Therapeutics Revenue
5.8.3 Key Manufacturers in India
5.8.4 India Irritable Bowel Syndrome (IBS) Therapeutics Import and Export

6 Irritable Bowel Syndrome (IBS) Therapeutics Segment Market Analysis (by Type)
6.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Production by Type
6.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Type
6.3 Irritable Bowel Syndrome (IBS) Therapeutics Price by Type

7 Irritable Bowel Syndrome (IBS) Therapeutics Segment Market Analysis (by Application)
7.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Consumption by Application
7.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Consumption Market Share by Application (2014-2019)

8 Irritable Bowel Syndrome (IBS) Therapeutics Major Manufacturers Analysis
8.1 Abbott Laboratories
8.1.1 Abbott Laboratories Irritable Bowel Syndrome (IBS) Therapeutics Production Sites and Area Served
8.1.2 Abbott Laboratories Product Introduction, Application and Specification
8.1.3 Abbott Laboratories Irritable Bowel Syndrome (IBS) Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.1.4 Main Business and Markets Served
8.2 Synergy Pharmaceuticals
8.2.1 Synergy Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Production Sites and Area Served
8.2.2 Synergy Pharmaceuticals Product Introduction, Application and Specification
8.2.3 Synergy Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.2.4 Main Business and Markets Served
8.3 Sucampo Pharmaceuticals
8.3.1 Sucampo Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Production Sites and Area Served
8.3.2 Sucampo Pharmaceuticals Product Introduction, Application and Specification
8.3.3 Sucampo Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.3.4 Main Business and Markets Served
8.4 Valeant Pharmaceuticals International
8.4.1 Valeant Pharmaceuticals International Irritable Bowel Syndrome (IBS) Therapeutics Production Sites and Area Served
8.4.2 Valeant Pharmaceuticals International Product Introduction, Application and Specification
8.4.3 Valeant Pharmaceuticals International Irritable Bowel Syndrome (IBS) Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.4.4 Main Business and Markets Served
8.5 Ardelyx
8.5.1 Ardelyx Irritable Bowel Syndrome (IBS) Therapeutics Production Sites and Area Served
8.5.2 Ardelyx Product Introduction, Application and Specification
8.5.3 Ardelyx Irritable Bowel Syndrome (IBS) Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.5.4 Main Business and Markets Served
8.6 Astellas Pharma
8.6.1 Astellas Pharma Irritable Bowel Syndrome (IBS) Therapeutics Production Sites and Area Served
8.6.2 Astellas Pharma Product Introduction, Application and Specification
8.6.3 Astellas Pharma Irritable Bowel Syndrome (IBS) Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.6.4 Main Business and Markets Served
8.7 Novartis
8.7.1 Novartis Irritable Bowel Syndrome (IBS) Therapeutics Production Sites and Area Served
8.7.2 Novartis Product Introduction, Application and Specification
8.7.3 Novartis Irritable Bowel Syndrome (IBS) Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.7.4 Main Business and Markets Served
8.8 GlaxoSmithKline
8.8.1 GlaxoSmithKline Irritable Bowel Syndrome (IBS) Therapeutics Production Sites and Area Served
8.8.2 GlaxoSmithKline Product Introduction, Application and Specification
8.8.3 GlaxoSmithKline Irritable Bowel Syndrome (IBS) Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.8.4 Main Business and Markets Served
8.9 Ironwood Pharmaceuticals
8.9.1 Ironwood Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Production Sites and Area Served
8.9.2 Ironwood Pharmaceuticals Product Introduction, Application and Specification
8.9.3 Ironwood Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.9.4 Main Business and Markets Served

9 Development Trend of Analysis of Irritable Bowel Syndrome (IBS) Therapeutics Market
9.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Market Trend Analysis
9.1.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Market Size (Volume and Value) Forecast 2019-2025
9.2 Irritable Bowel Syndrome (IBS) Therapeutics Regional Market Trend
9.2.1 North America Irritable Bowel Syndrome (IBS) Therapeutics Forecast 2019-2025
9.2.2 Europe Irritable Bowel Syndrome (IBS) Therapeutics Forecast 2019-2025
9.2.3 China Irritable Bowel Syndrome (IBS) Therapeutics Forecast 2019-2025
9.2.4 Japan Irritable Bowel Syndrome (IBS) Therapeutics Forecast 2019-2025
9.2.5 Southeast Asia Irritable Bowel Syndrome (IBS) Therapeutics Forecast 2019-2025
9.2.6 India Irritable Bowel Syndrome (IBS) Therapeutics Forecast 2019-2025
9.3 Irritable Bowel Syndrome (IBS) Therapeutics Market Trend (Product Type)
9.4 Irritable Bowel Syndrome (IBS) Therapeutics Market Trend (Application)

10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.3 Irritable Bowel Syndrome (IBS) Therapeutics Customers

11 Market Dynamics
11.1 Market Trends
11.2 Opportunities
11.3 Market Drivers
11.4 Challenges
11.5 Influence Factors

12 Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Author List
13.4 Disclaimer

...

【掲載企業】

Abbott Laboratories、Synergy Pharmaceuticals、Sucampo Pharmaceuticals、Valeant Pharmaceuticals International、Ardelyx、Astellas Pharma、Novartis、GlaxoSmithKline、Ironwood Pharmaceuticals

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の過敏性腸症候群(IBS)治療薬市場 2019年(Global Irritable Bowel Syndrome (IBS) Therapeutics Market Professional Survey Report 2019)]についてメールでお問い合わせはこちらでお願いします。